A new study from The Hospital for Sick Children (SickKids) reveals the process underlying protein organization on cell ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

In two randomised phase 3 studies involving 480 participants aged 12 years and over, ivacaftor/tezacaftor/vanzacaftor was ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer ... One reason for that is that around 2,000 mutations in the CFTR gene can lead to CF, a disease caused by an imbalance in ...

gene therapy aiming to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease. The trial specifically focuses on adults with CF who ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Porosome Therapeutics, Inc. announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

Food allergy prevalence was lower in those with cystic fibrosis vs ... peanut sensitization in a mouse model with homozygous CFTR mutations,” Leeds told Healio.

Cystic fibrosis is an inherited lifelong disease that gets worse over time. It is estimated to affect 105,000 people worldwide. There are more than 2,000 known mutations in the CFTR gene ...

The aim is to improve lung function and reduce exacerbations for people with CF irrespective of their mutations, including those who genetically cannot benefit from CFTR modulators. “We are very ...